• Study will assess the safety, anti-tumor activity and PK profile for MBRC-101 in the treatment of multiple solid tumor cancers, including breast, non-small cell lung and other solid tumors
• MBRC-101 targets the EphA5 receptor tyrosine kinase, represents first of Company’s innovative ADC pipeline to enter clinical trials

SAN DIEGO (December 19, 2023) – MBrace™ Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of patients with cancer by developing novel antibody-drug conjugates (ADCs), today announced the successful initiation of patient dosing in its Phase 1/1b study evaluating MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment.

This first-in-human Phase 1/1b clinical trial (NCT06014658) is a multicenter, open-label, dose-escalation and dose-expansion study of MBRC-101 in patients with advanced metastatic solid tumors refractory to standard treatment. The primary objectives of the study are to determine the following parameters for MBRC-101: potential optimal biologically relevant doses (OBRD), maximum tolerated dose (MTD), safety profile, and anti-tumor activity.

Read full article on mbracetrx.com